eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 69
Original paper

Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer

Aleksander Celewicz, Marta Celewicz, Małgorzata Wężowska, Anita Chudecka-Głaz, Janusz Menkiszak, Elzbieta Urasińska

Pol J Pathol 2018; 69 (1): 42-47
Online publish date: 2018/05/07
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Cervical cancer is the third most common malignant neoplasm in women worldwide. HPV infection is the necessary factor for the cancer to develop. HPV DNA can be integrated into the genome of squamous epithelium and cause transcription of the viral oncoproteins and development of invasive cancer within 15-20 years. We assessed ICC co-expression of p16/Ki-67 proteins in smears collected from the uterine cervix and the association between p16/Ki-67 co-expression and cytologic and histologic results. Samples were collected from 93 women using liquid based cytology (LBC). Two microscopic slides were prepared: for Papanicolaou staining and ICC staining. Biopsy samples were collected from 43 women. Diagnosis of CIN 2+ was the endpoint of the study. p16/Ki-67 positive cells were found in women with: 1) a cytology result of ASC-US (3.59%), LSIL (2.22%), ASC-H (21.92%), HSIL (33.18%), SCC (72.22%) or NILM (3.44%); 2) a histopathologic result of CIN 1 (2.13%), CIN 2 (19.93%), CIN 3 (23.22%), SCC (69.72%) or normal histology (7.58%). p16/Ki-67 dual staining can increase the efficiency of screening methods and indicate women in whom further diagnostic procedures are required or those with extremely low risk of cancer. Sparing protocols will have a significant role in women of reproductive age.

cervical cancer, pap smear, cytology, p16/Ki-67, dual-stained cytology, HPV

Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [online]. Lyon: International Agency for Research on Cancer; 2013. Available at: [http://globocan.iarc.fr].
Walboomers J, Jacobs M, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
Kumar V, Cotran R, Robbins S. Robbins Basic Pathology. 7th edition. Urban i Partner, Wrocław 2005.
Harper DM. Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy 2008; 5: 313-324.
Rokita W. Analiza wartości diagnostycznej wybranych testów molekularnych i immunocytochemicznych w wykrywaniu zmian patologicznych szyjki macicy. Wydawnictwo Naukowe Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań 2011.
Bremner R., Cohen B., Sopta M., et al. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 1995; 15: 3256-65.
Beaudenon S, Huibregtse J. HPV E6, E6AP and cervical cancer. BMC Biochemistry 2008; 9 (Suppl 1): 4.
Lee W. The molecular basis of cancer suppression by the retinoblastoma gene. Princess Takamatsu Symp 1989; 20: 159-70.
Stoler M. Human papillomaviruses and cervical neoplasia: a model for carcinogene-sis. Int J Gynecol Pathol 2000; 19: 16-28.
Ikenberg H, Bergeron C, Schmidt D, et al. Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study. Journal of the National Cancer Institute 2013; 105: 1550-1557.
Saslow D., Solomon D., Lawson H., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. J Low Genit Tract Dis 2012; 16: 175-204.
Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-953.
Fujii T, Saito M, Hasegawa T, et al. Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion specimens: a Japanese Gynecologic Oncology Group study. Int J Clin Oncol 2015; 20: 134-142.
Wentzensen N, Schwartz L, Zuna R, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012; 18: 4154–4162.
Schmidt D, Bergeron C, Denton K, et al. p16/Ki-67 Dualstain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European Equivocal or Mildly Abnormal Pap Cytology Study (EEMAPS). Cancer Cytopathol 2011; 119: 158-166.
Wentzensen N, Fetterman B, Tokugawa D, et al. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathology 2014; 122: 914-920.
Negri G, Vittadello F, Romano F, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004; 445: 616-620.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe